A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called elinzanetant to help women who have hot flashes after menopause. The medication works by blocking signals that cause hot flashes. Researchers will track the number and severity of hot flashes over time.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, the doctors will ask about the medicines you are taking, so it's best to discuss your specific situation with them.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either elinzanetant or placebo for 26 weeks. Placebo group switches to elinzanetant after 12 weeks.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Elinzanetant
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bayer
Lead Sponsor
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD